Application of medicine composition in preparation of medicine for improving immunity

Abstract

The invention is applicable to the technical field of biological medicines, and provides an application of a pharmaceutical composition in preparation of a medicine for improving immunity, the pharmaceutical composition comprises the following raw materials in percentage by weight: 45-6% of ginsenoside Rh, 2-4% of ginsenoside Rk3, 20-30% of ginsenoside Rg3, 3-15% of ginsenoside Rg513, 18-10% of ginsenoside Rk8, and the balance of ginseng extract, totaling 100%. The pharmaceutical composition provided by the invention can enhance the activity of immune cells, regulate the function of an immune system and realize efficient absorption and utilization so as to comprehensively improve the immunocompetence of a body, strengthen physique and help to resist disease invasion, and meanwhile, the pharmaceutical composition as a traditional Chinese medicine has extremely high stability and no toxic or side effect, and is suitable for people at all stages.

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to the application of a pharmaceutical composition in the preparation of a drug for improving immunity. Background Art

[0002] In the fast-paced world of modern life, the body's immune system generally declines due to factors such as unhealthy eating habits, poor sleep and work schedules, chronic stress, and aging. Immunity is not only the first line of defense against disease, effectively resisting the invasion of pathogens such as bacteria and viruses and reducing the risk of infection, but also accelerates pathogen clearance when illness strikes, shortening the course of illness, reducing complications, and promoting rapid recovery. Furthermore, strong immunity helps maintain a stable internal environment, regulate physiological functions, slow the aging process, and improve quality of life and well-being. It also enhances the body's antioxidant capacity, reduces free radical damage to cells, and maintains vitality and health. Therefore, boosting immunity is key to maintaining health and preventing chronic disease, and is a key goal in people's pursuit of a healthy lifestyle.

[0003] Existing immunity-boosting products have numerous shortcomings. First, while some products, such as probiotics, contribute to intestinal health, there's currently insufficient evidence to demonstrate their effectiveness in boosting systemic immunity. While bovine colostrum contains nutrients, its antibody components haven't been scientifically proven to enhance the human immune system, and its high estrogen content may also cause other health problems. Furthermore, excessive intake of supplements like protein powder can burden the kidneys if the daily diet is adequate. Some immune-boosting drugs, such as pidotimod, have unclear pharmacological effects and are even subject to restrictions. Overall, most of these products lack clear scientific evidence and may pose potential risks to specific populations. Summary of the Invention

[0004] The purpose of the embodiments of the present invention is to provide an application of a pharmaceutical composition in the preparation of a drug for improving immunity, aiming to solve the problems raised in the above background technology.

[0005] An embodiment of the present invention is achieved by using a pharmaceutical composition for preparing a drug for improving immunity, wherein the pharmaceutical composition comprises the following raw materials in weight percentage: ginsenoside Rh45-6%, ginsenoside Rk32-4%, ginsenoside Rg320-30%, ginsenoside Rg513-15%, ginsenoside Rk18-10%, and the remainder of ginseng extract is made up to 100%.

[0006] Preferably, the pharmaceutical composition comprises the following raw materials in the following weight percentages: ginsenoside Rh 46%, ginsenoside Rk 33%, ginsenoside Rg 320%, ginsenoside Rg 514%, ginsenoside Rk 19%, and ginseng extract 48%.

[0007] Preferably, the pharmaceutical composition comprises the following raw materials in the following weight percentages: ginsenoside Rh 45%, ginsenoside Rk 33%, ginsenoside Rg 330%, ginsenoside Rg 513%, ginsenoside Rk 19%, and ginseng extract 40%.

[0008] Preferably, the preparation method of the pharmaceutical composition comprises the following steps:

[0009] Preparation of ginseng extract: Ginseng powder obtained by crushing ginseng is mixed with ethanol, the extract is heated and filtered to obtain a first filtrate and a first filter residue, the first filter residue is mixed with ethanol, the extract is heated and filtered to obtain a second filtrate and a second filter residue, the first filtrate and the second filtrate are combined, concentrated, and dried to obtain the ginseng extract;

[0010] Ginsenoside Rh4, ginsenoside Rk3, ginsenoside Rg3, ginsenoside Rg5, and ginsenoside Rk1 are mixed with ginseng extract.

[0011] Preferably, the ginseng is one or more of white ginseng, fresh ginseng and red ginseng.

[0012] Preferably, the mass volume ratio of the ginseng powder to ethanol is 1:10-20.

[0013] Preferably, the mass volume ratio of the filter residue 1 to ethanol is 1:10-20.

[0014] An embodiment of the present invention provides an application of a pharmaceutical composition in the preparation of a drug for improving immunity, wherein the pharmaceutical composition comprises ginsenoside Rh4, ginsenoside Rk3, ginsenoside Rg3, ginsenoside Rg5, ginsenoside Rk1 and ginseng extract as active ingredients, can enhance the activity of immune cells, regulate the function of the immune system, and be efficiently absorbed and utilized, thereby comprehensively improving the body's immune capacity, strengthening the physical fitness, and helping to resist disease invasion. At the same time, as a traditional Chinese medicine, it has extremely strong stability, is free of any toxic side effects, and is suitable for people of all stages. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is a diagram of mouse spleen histopathology results provided in Example 4 of the present invention;

[0016] Figure 2 This is a graph showing the results of the inflammatory factor content in mouse serum provided in Example 5 of the present invention. DETAILED DESCRIPTION

[0017] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0018] The sources of ginsenosides Rh4, Rk3, Rg3, Rg5 and Rk1 can be naturally extracted, and can be extracted from wild ginseng, garden ginseng, American ginseng, etc., and the extraction method preferably includes one or more of organic solvent extraction, water extraction, ultrasonic impregnation, extraction, distillation, osmosis, and macroporous adsorption resin separation methods. In addition, these saponins can also be obtained by converting other diol or triol ginsenosides, for example, Rk1 and Rg5 can be converted from Rb1, and Rh4 and Rk3 can be converted from Rg1. The conversion method is preferably a bioconversion method. They can also be purchased directly.

[0019] Ginsenoside Rh4, ginsenoside Rk3, ginsenoside Rg3, ginsenoside Rg5, and ginsenoside Rk1 used in the examples of the present invention were all purchased from Shanghai Yuanye Biotechnology Co., Ltd., and their purity met the pharmaceutical standards.

[0020] The method for extracting the ginseng extract used in the embodiment of the present invention comprises the following steps:

[0021] Accurately weigh a certain amount of ginseng powder, put it into an extraction container, add 75% ethanol according to a certain material-liquid ratio (volume ratio of ginseng powder to ethanol), the common material-liquid ratio is 1:10 to 1:20, and more preferably 1:15, heat at 75°C for 3 hours (water bath heating method), filter the extract, and store the filtrate in a 4°C refrigerator. Add new ethanol to the remaining residue for a second extraction, repeat twice, and store the filtrate in a 4°C refrigerator; finally, combine the filtrates obtained from the two times, concentrate the filtered extract at normal pressure, remove ethanol, obtain a concentrated solution, and further dry the concentrated solution to obtain a ginseng extract; the ginseng extract includes ginsenoside components (Rg1, Re, Rf, Rb1, Rc and Rd), ginseng polysaccharide components, ginseng polypeptide components, ginseng polyphenol components and ginseng flavonoid components.

[0022] The specific implementation of the present invention is described in detail below with reference to specific embodiments.

[0023] Example 1: A pharmaceutical composition, the preparation method of which comprises the following steps:

[0024] (1) Preparation of ginseng extract: Weigh 20 g of ginseng powder, mix the crushed ginseng with 300 ml of ethanol (75%), heat at 75°C for 3 h, and filter the extract to obtain filtrate 1 and filter residue 1. Add 150 ml of ethanol to the filter residue 1 for a second extraction, heat at 75°C for 3 h, and filter the extract to obtain filtrate 2 and filter residue 2. Combine the two filtrates, concentrate the filtered extract at normal pressure to remove ethanol, and obtain a concentrated solution. The concentrated solution is further dried to obtain ginseng extract.

[0025] (2) Weigh the ingredients according to the weight percentage of ginsenoside Rh 46%, ginsenoside Rk 33%, ginsenoside Rg 320%, ginsenoside Rg 514%, ginsenoside Rk 19%, and ginseng extract 48%, and mix them.

[0026] Example 2: A pharmaceutical composition, the preparation method of which comprises the following steps:

[0027] (1) Preparation of ginseng extract: Weigh 20 g of ginseng powder, mix the crushed ginseng with 300 ml of ethanol (75%), heat at 75°C for 3 h, and filter the extract to obtain filtrate 1 and filter residue 1. Add 150 ml of ethanol to the filter residue 1 for a second extraction, heat at 75°C for 3 h, and filter the extract to obtain filtrate 2 and filter residue 2. Combine the two filtrates, concentrate the filtered extract at normal pressure to remove ethanol, and obtain a concentrated solution. The concentrated solution is further dried to obtain ginseng extract.

[0028] (2) Weigh the ingredients according to the weight percentage of ginsenoside Rh 45%, ginsenoside Rk 33%, ginsenoside Rg 330%, ginsenoside Rg 513%, ginsenoside Rk 19%, and ginseng extract 40%, and mix them.

[0029] Example 3, Biosafety Analysis of Pharmaceutical Compositions:

[0030] Mice (BALB / C mice, purchased from Liaoning Changsheng Biotechnology Co., Ltd.) were randomly divided into a negative control group (male), a pharmaceutical composition A group (male), a pharmaceutical composition B group (male), a negative control group (female), a pharmaceutical composition A group (female), and a pharmaceutical composition B group (female) according to sex, and fasted for 16 hours but not water; starting at 8:00 a.m., pharmaceutical composition A (Example 1) and pharmaceutical composition B (Example 2) were gavage-administered to the mice that had fasted for 16 hours, and the male and female mice in the negative control group were gavage-administered with an equal volume of purified water. Immediately after exposure, the mice were observed and their various poisoning symptoms were recorded; starting at 16:00 p.m., the mice were gavage-administered once more, and their various poisoning symptoms were continuously observed and recorded after exposure. The observation was continued for 14 days, and the results are shown in Table 1:

[0031] Table 1

[0032]

[0033]

[0034] As can be seen from Table 1, when the maximum dosage concentration and maximum dosage volume were administered by gavage twice within 24 hours, that is, at the maximum dosage of 24.0 g / kg, there were no obvious abnormalities in the body shape, limb activity, respiration, coat color, and feces and bowel movements of the mice compared with the control group; and the drug composition had no obvious effect on the body weight of both male and female mice.

[0035] Example 4: Experimental analysis of the pharmaceutical composition for enhancing the immune organ function in mice:

[0036] After observing the weight and condition of the mice, pathological examinations were performed on the main organs of the mice, including the heart, liver, spleen, lung, kidney, testicle, and ovary. The results were as follows: Figure 1 As shown, according to Figure 1 It can be seen that the pharmaceutical compositions provided in the embodiments of the present invention can increase the distribution of white marrow components in the spleen of mice, have the function of improving the immunity of mice, and no obvious, regular drug-related histomorphological changes were found in the tissues and organs of other major organs (heart, liver, lungs, kidneys, ovaries and testicles).

[0037] Example 5: Experimental analysis of the effect of the pharmaceutical composition on inflammatory factors:

[0038] Mice were randomly divided into a PBS control group, an APAP model group, a pharmaceutical composition A group, and a pharmaceutical composition B group. Pharmaceutical composition A (Example 1) and pharmaceutical composition B (Example 2) were administered orally to the mice for 7 days. After the 7th day, the mice in the PBS control group were administered orally with an equal volume of PBS, and the mice in the APAP model group and the pharmaceutical composition A and pharmaceutical composition B groups were intraperitoneally injected with equal concentrations of APAP solution. After 24 hours, the mice were killed to collect whole blood and obtain liver tissue for future use. In order to study the effect of the pharmaceutical composition on inflammatory factors, the levels of inflammatory cytokines TNF-α, IL-6, and IL-1β in serum were detected using enhanced fluorescence protein chip. The results are as follows: Figure 2 As shown, according to Figure 2 It can be seen that the levels of TNF-α, IL-6, and IL-1β in the serum of the model group were significantly higher than those in the PBS control group, while the levels of TNF-α, IL-6, and IL-1β in the serum of mice in the two drug composition treatment groups were significantly lower than those in the APAP model group.

[0039] In summary, the pharmaceutical composition provided by the embodiment of the present invention has good biosafety, can increase the distribution of white pulp components in the spleen of mice, has the function of improving the immunity of mice, and at the same time, in terms of anti-inflammatory, can significantly inhibit inflammation, which is statistically significant.

[0040] The above results show that both of the above two pharmaceutical compositions can inhibit the content of inflammatory factors in mouse serum, thereby playing a role in inhibiting inflammation.

[0041] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. Use of a pharmaceutical composition in the preparation of a drug for improving immunity, characterized in that: The pharmaceutical composition comprises the following raw materials in percentage by weight: ginsenoside Rh 45-6%, ginsenoside Rk 32-4%, ginsenoside Rg 320-30%, ginsenoside Rg 513-15%, ginsenoside Rk 18-10%, and the remainder of ginseng extract is supplemented to 100%.

2. Use of the pharmaceutical composition according to claim 1 in preparing a drug for improving immunity, characterized in that: The pharmaceutical composition comprises the following raw materials in percentage by weight: 46% of ginsenoside Rh, 33% of ginsenoside Rk, 320% of ginsenoside Rg, 514% of ginsenoside Rg, 19% of ginsenoside Rk, and 48% of ginseng extract.

3. Use of the pharmaceutical composition according to claim 1 in preparing a drug for improving immunity, characterized in that: The pharmaceutical composition comprises the following raw materials in percentage by weight: 45% of ginsenoside Rh, 33% of ginsenoside Rk, 330% of ginsenoside Rg, 513% of ginsenoside Rg, 19% of ginsenoside Rk, and 40% of ginseng extract.

4. Use of the pharmaceutical composition according to any one of claims 1 to 3 in the preparation of a drug for improving immunity, characterized in that: The preparation method of the pharmaceutical composition comprises the following steps: Preparation of ginseng extract: Ginseng powder obtained by crushing ginseng is mixed with ethanol, the extract is heated and filtered to obtain a first filtrate and a first filter residue, the first filter residue is mixed with ethanol, the extract is heated and filtered to obtain a second filtrate and a second filter residue, the first filtrate and the second filtrate are combined, concentrated, and dried to obtain the ginseng extract; Ginsenoside Rh4, ginsenoside Rk3, ginsenoside Rg3, ginsenoside Rg5, and ginsenoside Rk1 are mixed with ginseng extract.

5. Use of the pharmaceutical composition according to claim 4 in preparing a drug for improving immunity, characterized in that: The ginseng is one or more of white ginseng, fresh ginseng and red ginseng.

6. Use of the pharmaceutical composition according to claim 4 in preparing a drug for improving immunity, characterized in that: The mass volume ratio of the ginseng powder to ethanol is 1:10-20.

7. Use of the pharmaceutical composition according to claim 4 in preparing a drug for improving immunity, characterized in that: The mass volume ratio of the filter residue 1 to ethanol is 1:10-20.

Images